Fig. 3.
CpG 2006 ODN administration reduces AML tumorigenicity by more than 100-fold.
B6 mice (n = 10 per group) were challenged with various C1498 doses, as indicated. A cohort of mice was treated with CpG 2006 ODN, beginning on day −2. Mice receiving CpG 2006 survived significantly (P ≤ .03) longer than all groups, including those that received 100-fold fewer C1498 cells (2 × 104cells/mouse).
